Top

Published in:

01-08-2015 | Review

A therapeutic role for vitamin D on obesity-associated inflammation and weight-loss intervention

Authors: Aaron L. Slusher, Matthew J. McAllister, Chun-Jung Huang

Published in: Inflammation Research | Issue 8/2015

Abstract

Vitamin D plays an essential role in the regulation of skeletal metabolism as well as calcium and phosphate homeostasis, while vitamin D receptor (VDR) regulates de novo lipid synthesis, thereby contributing to the development of obesity. Furthermore, obese individuals are at a greater risk for vitamin D deficiency which may increase the potential risk for chronic inflammation, insulin resistance, and metabolic syndrome. While acute exercise enhances the activation of inflammatory signaling pathways, chronic exercise training may attenuate elevated pro-inflammatory cytokine production, resulting in the improvement of cardiovascular and metabolic health in obese individuals. Supplementation with vitamin D coupled with exercise or mild caloric restriction has been shown to improve markers of fitness and inflammation as well as cholesterol. Therefore, this review primarily addresses the impact of vitamin D deficiency in obesity-related inflammatory imbalances and how exercise and weight-loss interventions may enhance the beneficial effects on vitamin D-mediated inflammation in obesity.

MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76:1536–8.PubMedCentralPubMed

Bischoff-Ferrari H, Borchers M, Gudat F, Dürmüller U, Stähelin H, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19:265–9.PubMed

McGill A-T, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J. 2008;7:4.PubMedCentralPubMed

Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am Heart J. 2014;167:283–91.PubMed

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.PubMed

Miettinen ME, Kinnunen L, Leiviskä J, Keinänen-Kiukaanniemi S, Korpi-Hyövälti E, Niskanen L, Oksa H, Saaristo T, Tuomilehto J, Vanhala M. Association of serum 25-hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: population-based cross-sectional study (FIN-D2D). PLoS ONE. 2014;9:e100235.PubMedCentralPubMed

Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2007;72:690–3.

Khoo A-L, Chai LY, Koenen HJ, Kullberg B-J, Joosten I, van der Ven AJ, Netea MG. 1, 25-Dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis. 2011;203:122–30.PubMedCentralPubMed

Li B, Baylink DJ, Deb C, Zannetti C, Rajaallah F, Xing W, Walter MH, Lau K-HW, Qin X. 1, 25-Dihydroxyvitamin D3 suppresses TLR8 expression and TLR8-mediated inflammatory responses in monocytes in vitro and experimental autoimmune encephalomyelitis in vivo. PLoS ONE. 2013;8:e58808.PubMedCentralPubMed

10.

Gao D, Trayhurn P, Bing C. 1, 25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond). 2013;37:357–65.PubMedCentral

11.

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.PubMed

12.

Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.PubMed

13.

Braith RW, Stewart KJ. Resistance exercise training its role in the prevention of cardiovascular disease. Circulation. 2006;113:2642–50.PubMed

14.

Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud’homme D, Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetesa randomized trial. Ann Intern Med. 2007;147:357–69.PubMed

15.

Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29.PubMedCentralPubMed

16.

Cannell JJ, Hollis BW, Sorenson MB, Taft TN, Anderson J. Athletic performance and vitamin D. Med Sci Sports Exerc. 2009;41:1102–10.PubMed

17.

Mozoåowski W. Jäccaron; drzej Sniadecki (1768–1838) on the cure of rickets. Nature. 1939;143:121.

18.

IVlyton C. The geographical distribution and etiology of rickets. By Theobald A. Palm, MA, MD. The Practitioner 1890:45:270.

19.

Mellanby E. The part played by an “accessory factor” in the production of experiental rickets. J Physiol. 1918–1919;52:xi–xii, liii–liv.

20.

McCollum EF, Simmonds N, Becker JE, Shipley PG. Studies on experimental rickets: and experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem. 1922;53:293–312.

21.

Windaus A, Linsert O, Luttringhaus A, Weidlinch G. Über das krystallisierte vitamin D2. Justus Liebigs Ann Chem. 1932;492:226–31.

22.

Angus TC, Askew FA, Bourdillon RB, Bruce HM, Callow R, Fischmann C, Philpot L, Webster TA. A crystalline antirachitic substance. Proc Royal Soc Ser B. 1931;108:340–59.

23.

Windaus A, Schenck F, von Werder F. Über das antirachitisch wirksame Bestrahlungsproduct aus 7-Dehydrocholesterin. HoppeSeylers Ztschr Physiol Chem. 1936;241:100–3.

24.

Holick MF, MacLaughlin J, Clark M, Holick S, Potts J, Anderson R, Blank I, Parrish J, Elias P. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210:203–5.PubMed

25.

Tian XQ, Chen TC, Matsuoka L, Wortsman J, Holick M. Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem. 1993;268:14888–92.PubMed

26.

MacLaughlin JA, Anderson R, Holick MF. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science. 1982;216:1001–3.PubMed

27.

Havinga E. Vitamin D, example and challenge. Experientia. 1973;29:1181–93.PubMed

28.

Dubnov-Raz G, Livne N, Raz R, Cohen A, Constantini, N. Vitamin D supplementation and physical performance in adolescent swimmers. Int J Sport Nutr Exerc Metab. 2014 (Epub ahead of print).

29.

Mutt SJ, Hypponen E, Saarnio J, Järvelin M-R, Herzig K-H. Vitamin D and adipose tissue-more than storage. Front Physiol. 2014;5:228.PubMedCentralPubMed

30.

Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116:2062–72.PubMedCentralPubMed

31.

Blunt J, DeLuca H, Schnoes H. 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry. 1968;7:3317–22.PubMed

32.

DeLuca H, Holick M, Schnoes H, Suda T, Cousins R. Isolation and identification of 1, 25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry. 1971;10:2799–804.PubMed

33.

Martini LA, Wood RJ. Vitamin D status and the metabolic syndrome. Nutr Rev. 2006;64:479–86.PubMed

34.

Holick MF, MacLaughlin J, Doppelt S. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1981;211:590–3.PubMed

35.

Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64:1165–8.PubMed

36.

Clemens T, Henderson S, Adams J, Holick M. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;319:74–6.

37.

Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol. 1991;127:536–8.PubMed

38.

Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in boston and edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67:373–8.PubMed

39.

Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79:362–71.PubMed

40.

Tan C, Statham B, Marks R, Payne P. Skin thickness measurement by pulsed ultrasound; its reproducibility, validation and variability. Br J Dermatol. 1982;106:657–67.PubMed

41.

Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL, Robins SJ, O’Donnell CJ, Hoffmann U, Jacques PF. Adiposity, cardiometabolic risk, and vitamin D status: The Framingham Heart Study. Diabetes. 2010;59:242–8.PubMedCentralPubMed

42.

Heaney RP, Holick MF. Why the iom recommendations for vitamin d are deficient. J Bone Miner Res. 2011;26:455–7.PubMed

43.

Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.PubMedCentralPubMed

44.

DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–96S.PubMed

45.

Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.PubMedCentralPubMed

46.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.PubMed

47.

Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo D-H, Thomas J. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95:4584–91.PubMed

48.

Aloia JF, Patel M, DiMaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87:1952–8.PubMed

49.

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.PubMedCentralPubMed

50.

Trang HM, Cole D, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68:854–8.PubMed

51.

Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387–91.PubMed

52.

Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1, 25-dihydroxyvitamin D2 and 1, 25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98:973–9.PubMedCentralPubMed

53.

Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677–81.PubMedCentralPubMed

54.

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806–14.PubMed

55.

Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R. Serum 1, 25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr. 2008;47:87–91.PubMed

56.

Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, Yanovski JA. The relationship between obesity and serum 1, 25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89:1196–9.PubMed

57.

Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and vitamin D deficiency: a systemic review and meta-analysis. Obes Rev. 2015;16:341–9.PubMed

58.

Compston JE, Vedi S, Ledger JE, Webb A, Gazet J-C, Pilkington T. Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr. 1981;34:2359–63.PubMed

59.

Kamycheva E, Joakimsen RM, Jorde R. Intakes of calcium and vitamin D predict body mass index in the population of Northern Norway. J Nutr. 2003;133:102–6.PubMed

60.

Rodríguez-Rodríguez E, Navia B, López-Sobaler AM, Ortega RM. Vitamin D in overweight/obese women and its relationship with dietetic and anthropometric variables. Obesity (Silver Spring). 2009;17:778–82.

61.

Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcif Tissue Int. 1988;43:199–201.PubMed

62.

Rosenstreich SJ, Rich C, Volwiler W. Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J Clin Invest. 1971;50:679–87.PubMedCentralPubMed

63.

Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228–30.PubMed

64.

Mitri J, Muraru M, Pittas A. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65:1005–15.PubMedCentralPubMed

65.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.PubMed

66.

Norman AW. Vitamin d receptor: new assignments for an already busy receptor. Endocrinology. 2006;147:5542–8.PubMed

67.

Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9:941–55.PubMed

68.

Demay MB. Mechanism of vitamin D receptor action. Ann NY Acad Sci. 2006;1068:204–13.PubMed

69.

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835–9.PubMed

70.

Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hollenberg AN. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J Biol Chem. 2006;281:11205–13.PubMed

71.

Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr. 2012;108:1915–23.PubMed

72.

Stephens JM. The fat controller: adipocyte development. PLoS Biol. 2012;10:e1001436.PubMedCentralPubMed

73.

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–51.PubMed

74.

Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch F-G, Cuvelier C, Ruige J, Eckardt K, Ouwens DM. Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics. 2012;11(M111):010504.PubMed

75.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.PubMedCentralPubMed

76.

Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.PubMedCentralPubMed

77.

Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.PubMedCentralPubMed

78.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.PubMed

79.

Vlasova M, Purhonen A, Jarvelin M, Rodilla E, Pascual J, Herzig K. Role of adipokines in obesity-associated hypertension. Acta Physiol (Oxf). 2010;200:107–27.PubMed

80.

Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M. Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89–90:121–5.PubMed

81.

Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1α-hydroylase in human brain. J Chem Neuroanat. 2005;29:21–30.PubMed

82.

Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621–91.PubMed

83.

Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;5:1666–71.

84.

Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK, Burgess JR, Teegarden D. 1α,25-dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol. 2008;112:122–6.PubMedCentralPubMed

85.

Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010;39:365–79.PubMedCentralPubMed

86.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMed

87.

vinh qu

https://static-content.springer.com/image/art%3A10.1007%2Fs00011-015-0847-4/MediaObjects/11_2015_847_Figa_HTML.gif

c L

https://static-content.springer.com/image/art%3A10.1007%2Fs00011-015-0847-4/MediaObjects/11_2015_847_Figc_HTML.gif

https://static-content.springer.com/image/art%3A10.1007%2Fs00011-015-0847-4/MediaObjects/11_2015_847_Figd_HTML.gif

ng K, Nguy

https://static-content.springer.com/image/art%3A10.1007%2Fs00011-015-0847-4/MediaObjects/11_2015_847_Figb_HTML.gif

n LT. The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms. Nutr J. 2013;12:89.

88.

Vitseva OI, Tanriverdi K, Tchkonia TT, Kirkland JL, McDonnell ME, Apovian CM, Freedman J, Gokce N. Inducible toll-like receptor and NF-κB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring). 2008;16:932–7.PubMedCentralPubMed

89.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84.PubMed

90.

Könner AC, Brüning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab. 2011;22:16–23.

91.

Creely SJ, McTernan PG, Kusminski CM, Da Silva N, Khanolkar M, Evans M, Harte A, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.PubMed

92.

Scholtes VP, Versteeg D, de Vries J-PP, Hoefer IE, Schoneveld AH, Stella PR, Doevendans PA, van Keulen KJ, de Kleijn DP, Moll FL. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. Clin Sci. 2011;121:205–14.PubMed

93.

Kim S-J, Choi Y, Choi Y-H, Park T. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem. 2012;23:113–22.PubMed

94.

Davis JE, Braucher DR, Walker-Daniels J, Spurlock ME. Absence of TLR2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. J Nutr Biochem. 2011;22:136–41.PubMed

95.

Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56:1986–98.PubMed

96.

Khoo AL, Chai L, Koenen H, Sweep F, Joosten I, Netea M, van der Ven A. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol. 2011;164:72–9.PubMedCentralPubMed

97.

Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.PubMed

98.

Petchey WG, Johnson DW, Isbel NM. Shining D’light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton). 2011;16:351–67.

99.

Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007;86:959–64.PubMed

100.

Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for jnk in obesity and insulin resistance. Nature. 2002;420:333–6.PubMed

101.

Nguyen MA, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi N-W, Olefsky JM. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 2005;280:35361–71.PubMed

102.

Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993;75:487–93.PubMed

103.

Ito A, Suganami T, Miyamoto Y, Yoshimasa Y, Takeya M, Kamei Y, Ogawa Y. Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem. 2007;282:25445–52.PubMed

104.

Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687–98.PubMedCentralPubMed

105.

Lorente-Cebrián S, Eriksson A, Dunlop T, Mejhert N, Dahlman I, Aström G, Sjölin E, Wåhlén K, Carlberg C, Laurencikiene J, Hedén P, Arner P, Rydén M. Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr. 2012;51:335–42.PubMed

106.

Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. J Biol Chem. 2013;5:19450–8.

107.

Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol. 2001;145:351–7.PubMed

108.

Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23–33.PubMed

109.

Zhang X, Zhou M, Guo Y, Song Z, Liu B. 1,25-dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPARγ signaling pathway. Biomed Res Int. 2015;2015:157834.PubMedCentralPubMed

110.

Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;25:129–39.

111.

Do Lee C, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69:373–80.

112.

Lee D-C, Sui X, Artero EG, Lee I-M, Church TS, McAuley PA, Stanford FC, Kohl HW, Blair SN. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men the aerobics center longitudinal study. Circulation. 2011;124:2483–90.PubMedCentralPubMed

113.

Kullo IJ, Khaleghi M, Hensrud DD. Markers of inflammation are inversely associated with VO2 max in asymptomatic men. J Appl Physiol. 1985;2007(102):1374–9.

114.

Mowry DA, Costello MM, Heelan KA. Association among cardiorespiratory fitness, body fat, and bone marker measurements in healthy young females. J Am Osteopath Assoc. 2009;109:534–9.PubMed

115.

Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am J Physiol Endocrinol Metab. 2010;298:E824–31.PubMed

116.

Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjær-Kristensen J, Pedersen BK. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol. 1985;2001(91):1708–12.

117.

Steensberg A, Toft AD, Schjerling P, Halkjær-Kristensen J, Pedersen BK. Plasma interleukin-6 during strenuous exercise: role of epinephrine. Am J Physiol Cell Physiol. 2001;281:C1001–4.PubMed

118.

Yamada M, Suzuki K, Kudo S, Totsuka M, Nakaji S, Sugawara K. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. J Appl Physiol. 1985;2002(92):1789–94.

119.

Smith L, Anwar A, Fragen M, Rananto C, Johnson R, Holbert D. Cytokines and cell adhesion molecules associated with high-intensity eccentric exercise. Eur J Appl Physiol. 2000;82:61–7.PubMed

120.

MacIntyre DL, Sorichter S, Mair J, Berg A, McKenzie DC. Markers of inflammation and myofibrillar proteins following eccentric exercise in humans. Eur J Appl Physiol. 2001;84:180–6.PubMed

121.

Peake J, Nosaka KK, Muthalib M, Suzuki K. Systemic inflammatory responses to maximal versus submaximal lengthening contractions of the elbow flexors. Exerc Immunol Rev. 2006;12:72–85.PubMed

122.

Gokhale R, Chandrashekara S, Vasanthakumar K. Cytokine response to strenuous exercise in athletes and non-athletes—an adaptive response. Cytokine. 2007;40:123–7.PubMed

123.

Fischer CP, Plomgaard P, Hansen AK, Pilegaard H, Saltin B, Pedersen BK. Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004;287:E1189–94.PubMed

124.

Harris RA, Padilla J, Hanlon KP, Rink LD, Wallace JP. The flow-mediated dilation response to acute exercise in overweight active and inactive men. Obesity (Silver Spring). 2008;16:578–84.

125.

Christiansen T, Bruun JM, Paulsen SK, Ølholm J, Overgaard K, Pedersen SB, Richelsen B. Acute exercise increases circulating inflammatory markers in overweight and obese compared with lean subjects. Eur J Appl Physiol. 2013;113:1635–42.PubMed

126.

Ploeger HE, Takken T, De Greef M, Timmons BW. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc Immunol Rev. 2009;15:6–41.PubMed

127.

Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2005;290:E961–7.PubMed

128.

Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol. 2005;78:819–35.PubMed

129.

Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14 + cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun. 2005;19:389–97.PubMed

130.

Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Stepien A, Skibinska E, Szelachowska M, Kinalska I. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol. 2001;145:273–80.PubMed

131.

Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev. 2010;16:105–18.PubMed

132.

Phillips MD, Patrizi RM, Cheek DJ, Wooten JS, Barbee JJ, Mitchell JB. Resistance training reduces subclinical inflammation in obese, postmenopausal women. Med Sci Sports Exerc. 2012;44:2099–110.PubMed

133.

Kopp H-P, Kopp C, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042–7.PubMed

134.

Reinehr T, de Sousa G, Alexy U, Kersting M, Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol. 2007;157:225–32.PubMed

135.

Tzotzas T, Papadopoulou FG, Tziomalos K, Karras S, Gastaris K, Perros P, Krassas GE. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab. 2010;95:4251–7.PubMed

136.

Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S. Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab. 2008;93:2181–7.PubMedCentralPubMed

137.

Rosenblum JL, Castro VM, Moore CE, Kaplan LM. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr. 2012;95:101–8.PubMedCentralPubMed

138.

Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321–7.PubMed

139.

Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85:54–9.PubMed

140.

You T, Berman DM, Ryan AS, Nicklas BJ. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab. 2004;89:1739–46.PubMed

141.

Rayalam S, Della-Fera MA, Ambati S, Yang JY, Park HJ, Baile CA. Enhanced effects of 1,25(OH)2D3 plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring). 2008;16:539–46.PubMed

Title: A therapeutic role for vitamin D on obesity-associated inflammation and weight-loss intervention
Authors: Aaron L. Slusher
Matthew J. McAllister
Chun-Jung Huang
Publication date: 01-08-2015
Publisher: Springer Basel
Published in: Inflammation Research / Issue 8/2015
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-015-0847-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

Association of hydrogen sulfide with alterations of monocyte chemokine receptors, CCR2 and CX3CR1 in patients with coronary artery disease

Sesamol suppresses the inflammatory response by inhibiting NF-κB/MAPK activation and upregulating AMP kinase signaling in RAW 264.7 macrophages

Alterations in Hoffa’s fat pad induced by an inflammatory response following idealized anterior cruciate ligament surgery

Role of high-mobility group box 1 protein in inflammatory bowel disease

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation–coagulation interactions and reduces influenza virus-associated pulmonary damage

Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials